Subretinal gene therapy AGTC-501 for X-linked retinitis pigmentosa in the Phase 1/2 Horizon study: Post-hoc analysis of microperimetry results in the high dose groups

AGTC-501 - AGTC

David G. Birch1; Andreas K. Lauer2; Paul Yang2; Robert Sisk3,6; Rajiv Anand7,1; Darin Curtiss4; Amy Christenson4; Nadia K. Waheed4,5

Apr 15, 2024